Quote | PureTech Health plc (NYSE:PRTC)
Last: | $38.50 |
---|---|
Change Percent: | 16.67% |
Open: | $33 |
Close: | $38.50 |
High: | $38.75 |
Low: | $33 |
Volume: | 14,611 |
Last Trade Date Time: | 11/16/2020 04:57:55 pm |
News | PureTech Health plc (NYSE:PRTC)
2024-04-17 05:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Topline results are expected in Q4 2024 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in ...
Message Board Posts | PureTech Health plc (NYSE:PRTC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
PureTech Health plc Company Name:
PRTC Stock Symbol:
NYSE Market:
2024-04-17 05:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Topline results are expected in Q4 2024 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in ...
LYT-200 is being evaluated in locally advanced/metastatic solid tumors, including head and neck cancers, as well as in hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndrome Phase 1b and Phase 1/2 clinical trials of LYT-200 ongoing Pu...